# Intraarterial Infusion Of Erbitux and Bevacizumab For Relapsed/Refractory Intracranial Glioma In Patients Under 22

> **NCT01884740** · PHASE1,PHASE2 · TERMINATED · sponsor: **Weill Medical College of Cornell University** · enrollment: 13 (actual)

## Conditions studied

- Glioblastoma Multiforme
- Fibrillary Astrocytoma of Brain
- Glioma of Brainstem
- Anaplastic Astrocytoma
- Pilomyxoid Astrocytoma
- Mixed Oligodendroglioma-Astrocytoma
- Brain Stem Glioma
- Diffuse Intrinsic Pontine Glioma

## Interventions

- **DRUG:** SIACI of Erbitux and Bevacizumab

## Key facts

- **NCT ID:** NCT01884740
- **Lead sponsor:** Weill Medical College of Cornell University
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2013-06
- **Primary completion:** 2018-10
- **Final completion:** 2018-10
- **Target enrollment:** 13 (ACTUAL)
- **Why stopped:** The study was prematurely closed in December 2021 due to low accrual.
- **Last updated:** 2022-08-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01884740

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01884740, "Intraarterial Infusion Of Erbitux and Bevacizumab For Relapsed/Refractory Intracranial Glioma In Patients Under 22". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01884740. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*